Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
Google Halts UK YouTube TV Measurement Service After Legal Action 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics 
LONDON, May 23, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Jefferies Healthcare Conference
Date: June 8, 2017
Time: 11:30 AM EDT
Location: New York, NY
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||||
| Aubrey Powell / James White | ||||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||||
| ICR, Inc. (US Media and Investor enquiries) | ||||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
